Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG (MOLN) is a clinical-stage biotech company whose news flow is closely tied to the progress of its DARPin-based oncology pipeline. The company regularly issues updates on its clinical trials, preclinical data presentations and strategic collaborations, giving investors and observers insight into how its programs are advancing through development.
News about Molecular Partners often highlights milestones for its Radio-DARPin platform, including MP0712, a 212Pb-based candidate targeting DLL3 in small cell lung cancer and other neuroendocrine cancers, and MP0726, which targets mesothelin in cancers with high unmet need. Press releases describe regulatory steps such as Investigational New Drug applications, initiation of Phase 1/2a studies, and early human imaging data from compassionate care programs, as well as the role of its collaboration with Orano Med in radiotherapeutics.
Another major source of updates is the companys multispecific T cell engager MP0533, in Phase 1/2a for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome/AML. Molecular Partners reports interim clinical data, dosing refinements and response patterns, particularly in patients with lower disease burden, through conference presentations and ad hoc announcements. News items also cover MP0317, a tumor-localized CD40 agonist in an investigator-initiated Phase 2 trial in cholangiocarcinoma, and preclinical Switch-DARPin programs that use logic-gated immune activation.
Corporate communications further include quarterly and half-year financial results, cash runway commentary, and management changes such as the appointment of a Chief Scientific Officer. For readers following MOLN stock, this news page provides a centralized view of regulatory disclosures, scientific conference presentations and pipeline progress updates related to Molecular Partners DARPin therapeutics.
Molecular Partners (SIX/NASDAQ: MOLN) reported 2025 results and pipeline progress. Key clinical advances include the initiation of the Phase 1/2a study of MP0712 (DLL3, 212Pb) with initial imaging/dosimetry data and expected clinical readouts in 2026. The company ended 2025 with CHF 93.1M cash, funding operations into 2028, and a 2025 net loss of CHF 61.7M.
Other highlights: MP0726 advancing toward first-in-human imaging, a deal with Eckert & Ziegler for isotope access, ongoing Phase 2 investigator trial of MP0317 in cholangiocarcinoma, and an active MP0533 AML program with an update expected H1 2026.
Molecular Partners (SIX: MOLN; NASDAQ: MOLN) announced CEO Patrick Amstutz will present at two investor conferences in March 2026 and that the company will release its full-year 2025 financial results and Annual Report on March 12, 2026.
Fireside chats at TD Cowen (March 2) and Leerink Partners (March 9) will be available on the company investor website. The results release is scheduled for March 12 at 4:00 pm EDT (9:00 pm CET).
Molecular Partners (SIX: MOLN; NASDAQ: MOLN) signed a non-exclusive development agreement with Eckert & Ziegler to advance its Radio-DARPin pipeline using alpha and beta emitters.
The collaboration covers development and manufacturing support for Actinium-225 (225Ac) and Lutetium-177 (177Lu), leveraging Eckert & Ziegler’s Alpha Laboratory in Berlin. The company plans to present pre-clinical multi-isotope data at a March 2026 summit and notes its lead candidate MP0712 recently opened a Phase 1/2a trial in small cell lung cancer.
Molecular Partners (NYSE: MOLN) presented first-in-human imaging and dosimetry data for DLL3-targeting Radio-DARPin MP0712 at TWC 2026. Data from five evaluable patients using diagnostic 203Pb show tumor-specific uptake, favorable biodistribution, and dosimetry supporting a U.S. Phase 1/2a study of therapeutic 212Pb. The Phase 1/2a study is open in the U.S. with initial clinical data expected in 2026. A company webcast and conference call were held Feb 2, 2026, with commentary from Prof. Ken Herrmann.
Molecular Partners (NASDAQ:MOLN) provided a clinical update ahead of J.P. Morgan, reporting a cleared IND and the start of a Phase 1/2a trial for radio-DARPin MP0712 (DLL3) with first patient dosing expected in Q1 2026 and initial data anticipated in 2026. The company reported CHF 93.1 million cash as of Dec 31, 2025, sufficient to fund operations into 2028. Additional highlights: compassionate-program 203Pb imaging for MP0712 to be presented at TWC 2026; Phase 2 investigator-initiated trial of MP0317 in cholangiocarcinoma open (target 75 patients); ongoing Phase 1/2a for MP0533 with an update planned in H1 2026.
Molecular Partners (SIX/NASDAQ: MOLN) will present corporate and clinical updates at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026. CEO Patrick Amstutz will speak on Thursday, January 15, 2026 at 10:30–11:10 AM PT (19:30–20:10 CET) at the Westin St. Francis.
A live webcast of the presentation will be available via the company website under the Events tab. The presentation will cover the company’s latest developments and 2025 outlook.
Molecular Partners (SIX/NASDAQ: MOLN) formed a Scientific Advisory Board (SAB) for its radiopharmaceutical program, chaired by Prof. Ken Herrmann, M.D., to guide transition from early clinical validation to strategic development decisions.
The SAB includes James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D., and will advise on candidate development, platform expansion (additional isotopes and targeting), and clinical strategy. The company's lead Radio-DARPin MP0712 is a 212Pb-based DLL3-targeting candidate (co-developed with Orano Med) with first human images presented recently and plans for phase 1 initiation. A second program, MP0726, targets mesothelin for cancers including ovarian cancer. The release emphasizes Radio-DARPins as vectors to deliver alpha-emitting isotopes selectively to tumors.
Molecular Partners (NASDAQ: MOLN) presented updated Phase 1/2a data for tetra-specific T-cell engager MP0533 in relapsed/refractory AML at ASH on December 7, 2025. As of the September 1, 2025 cut-off, 54 patients received MP0533 and 8 of 48 evaluable patients responded (5 composite complete responses and 3 MLFS). Densified and higher-frequency dosing (cohorts 8–9) was tolerable, increased serum exposure in cycle 1, and showed preliminary antitumor activity. Responses clustered in patients with <20% bone marrow blasts at baseline. Cohort 10 is ongoing with data expected in 2026.
Molecular Partners (NASDAQ: MOLN) presented new human imaging and mechanism data for MP0712, a DLL3-targeting Radio-DARPin, at TRP Summit Europe on Nov 12, 2025. A named‑patient case from South Africa showed specific tumor uptake at 24 hours and sustained signal over 4 days using 203Pb imaging, with limited kidney and liver exposure. The company filed a Phase 1 IND for MP0712 and expects to initiate the US trial by end‑2025, with initial clinical data anticipated in 2026. Presentation and webcast details were provided for Nov 12, 2025.
Molecular Partners (NASDAQ: MOLN) will present additional preclinical proof-of-concept data on its logic-gated CD3 Switch-DARPin T cell engager with CD2 co-stimulation at SITC 2025 (Nov 5-9; poster Nov 7).
Preclinical results show the AND-gated Switch-DARPin selectively triggered T cell cytotoxicity only against cells co-expressing MSLN and EpCAM, improved T cell activation and proliferation with CD2/CD3 co-stimulation, and induced significant tumor regression in a xenograft model without systemic cytokine release, indicating a favorable safety signal.